Edition:
United Kingdom

VIVUS Inc (VVUS.OQ)

VVUS.OQ on NASDAQ Stock Exchange Global Select Market

0.55USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
135,926
52-wk High
$1.40
52-wk Low
$0.53

Chart for

About

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $102.34
Shares Outstanding(Mil.): 105.86
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Vivus reports third quarter 2017 financial results

* Vivus Inc - ‍total revenue, net for third quarters of 2017 and 2016, was $15.2 million and $13.4 million, respectively​

07 Nov 2017

BRIEF-VIVUS and Alvogen announce marketing agreement for Qsymia in the Republic of Korea

* VIVUS Inc - ‍Alvogen will be solely responsible for obtaining and maintaining regulatory approvals and for all sales and marketing activities in Korea​​

05 Sep 2017

BRIEF-Dr.Reddy's Labs says overall impact on financials of settlement disputes with Vivus not likely to be material

* Dr.Reddy's Laboratories clarifies on news item regarding settling patent row with vivus

01 Sep 2017

BRIEF-Vivus reports settlement with Dr. Reddy's laboratories on qsymia patent litigation

* Vivus announces settlement with Dr. Reddy's laboratories on qsymia(r) patent litigation

30 Aug 2017

BRIEF-Vivus announces settlement with Actavis on Qsymia patent litigation

* Vivus announces settlement with actavis on qsymia(r) patent litigation

05 Jul 2017

Earnings vs. Estimates